GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Construction In Progress

BIOYF (Biosyent) Construction In Progress : $0.00 Mil (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Biosyent Construction In Progress?


Biosyent Construction In Progress Historical Data

The historical data trend for Biosyent's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Construction In Progress Chart

Biosyent Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biosyent Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biosyent Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Biosyent Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.

Biosyent Headlines

From GuruFocus

Q2 2022 Biosyent Inc Earnings Presentation Transcript

By GuruFocus Research 02-12-2024

Biosyent Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-12-2024

Q4 2022 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q3 2021 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q4 2018 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q2 2021 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q2 2019 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024